<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647903</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-104</org_study_id>
    <nct_id>NCT04647903</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)</brief_title>
  <acronym>SEAL</acronym>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Placebo-, Active-Controlled, 4 Period, 4 Way Crossover Study to Evaluate the Abuse Potential of Manipulated Abuse-Deterrent Dextroamphetamine Sulfate Immediate Release (ADAIR) Formulation Compared to Dextroamphetamine Sulfate Immediate Release When Administered Intranasally to Nondependent, Recreational Stimulant Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vallon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vallon Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, double-dummy, placebo- and active-controlled 4 period, 4&#xD;
      way crossover study to assess the intranasal abuse potential of manipulated ADAIR formulation&#xD;
      in nondependent, recreational stimulant users. The study will consist of an outpatient&#xD;
      Screening Visit, an in clinic Qualification Phase, an in-clinic Treatment Phase, and an&#xD;
      outpatient Follow-Up visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VAL-104 is a phase 1, randomized, double-blind, double-dummy, placebo- and active-controlled&#xD;
      4 period, 4 way crossover study to assess the intranasal abuse potential of manipulated ADAIR&#xD;
      formulation in nondependent, recreational stimulant users. The study objectives include&#xD;
      assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of&#xD;
      manipulated ADAIR 30mg when compared to crushed d-amphetamine sulfate and placebo. The&#xD;
      primary PD endpoint is mean maximum drug liking (Emax) on a bipolar 100mm visual analog&#xD;
      scale.&#xD;
&#xD;
      A total of 64 subjects demonstrating a confirmed positive response to stimulants will enter&#xD;
      the treatment phase. Safety will be assess via adverse events, vital signs, ECGs, clinical&#xD;
      laboratory tests and Columbia Suicide Severity Rating Scale (C-SSRS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking Emax Visual Analog Scale (VAS)</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Peak effect for drug liking based on bipolar VAS from 0-100 scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again Emax VAS</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Peak effect for take drug again based on bipolar VAS from 0-100 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking Emax VAS</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Peak effect for overall drug liking based on bipolar VAS from 0-100 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations (PK parameters)</measure>
    <time_frame>Up to 36 hours post dose</time_frame>
    <description>plasma concentrations of ADAIR and dextroamphetamine sulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>Day 1 to Day 18</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>ADHD</condition>
  <condition>Narcolepsy</condition>
  <arm_group>
    <arm_group_label>Oral Placebo + Intranasal manipulated ADAIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Placebo + Intranasal manipulated ADAIR 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo + Intranasal crushed dextroamphetamine sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Placebo + Intranasal crushed dextroamphetamine sulfate IR 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ADAIR + Intranasal Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ADAIR 30 mg + Intranasal Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo + Intranasal Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo + Intranasal Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADAIR 10 mg IR tablets</intervention_name>
    <description>manipulated ADAIR 3x10mg</description>
    <arm_group_label>Oral Placebo + Intranasal manipulated ADAIR</arm_group_label>
    <other_name>ADAIR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-amphetamine sulfate</intervention_name>
    <description>crushed d-amphetamine sulfate 3x10mg</description>
    <arm_group_label>Oral Placebo + Intranasal crushed dextroamphetamine sulfate</arm_group_label>
    <other_name>dextroamphetamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for oral and intranasal administration</description>
    <arm_group_label>Oral ADAIR + Intranasal Placebo</arm_group_label>
    <arm_group_label>Oral Placebo + Intranasal Placebo</arm_group_label>
    <arm_group_label>Oral Placebo + Intranasal crushed dextroamphetamine sulfate</arm_group_label>
    <arm_group_label>Oral Placebo + Intranasal manipulated ADAIR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female volunteers, 18 to 55 years of age inclusive&#xD;
&#xD;
          -  Recreational drug abuse experience (&gt;/= 10 times lifetime abuse of a CNS stimulant,&#xD;
             &gt;/= 1 abuse of CNS stimulant in the previous 3 months)&#xD;
&#xD;
          -  Prior intranasal recreational drug abuse experience&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 33 kg/m2 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any significant disease or disorder&#xD;
&#xD;
          -  History or current diagnosis of substance dependence (excluding caffeine and nicotine)&#xD;
&#xD;
          -  Any confirmed significant allergic reactions against any drug, or multiple allergies&#xD;
             in the judgement of the investigator&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C or HIV infection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in an investigational drug or device study within the last 30 days prior&#xD;
             to Day 1 of the study&#xD;
&#xD;
          -  Confirmed positive drug screening&#xD;
&#xD;
          -  Positive alcohol breath test at screening / any Day -1&#xD;
&#xD;
          -  Heavy smoker (&gt; 20 cigarettes, &gt; 8 pipefuls or &gt; 8 cigars per day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Whitaker, M</last_name>
    <role>Study Director</role>
    <affiliation>Vallon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>484-802-7405</phone>
    <email>jessica@vallon-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vallon Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Study Manager</last_name>
      <phone>801-904-4519</phone>
      <email>bauerbrad@prahs.com</email>
    </contact>
    <contact_backup>
      <last_name>Clinical Study Specialist</last_name>
      <phone>801-269-8200</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently there is no IPD plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

